p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood.v81.1.128.128PMID 8417784
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clonal expansion of p53 mutant cells is associated with brain tumour progression

  1992cited by this paper
• p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

  1991cited by this paper
• The p53 tumour suppressor gene

  1991cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

  1991cited by this paper
• Mutations in the p53 gene in myelodysplastic syndromes.

  1991cited by this paper
• Analysis of tumor‐specific immunoglobulin gene rearrangement in peripheral blood B‐cells of multiple myeloma patients

  1991cited by this paper
• P53 gene mutations in acute myeloid leukemia with 17p monosomy.

  1991cited by this paper
• Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa

  1991cited by this paper
• Different tumor-derived p53 mutants exhibit distinct biological activities.

  1990cited by this paper
• Structural aspects of the p53 protein in relation to gene evolution.

  1990cited by this paper
• Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines

  1990cited by this paper
• p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

  1990cited by this paper
• p53: a frequent target for genetic abnormalities in lung cancer.

  1989cited by this paper
• Mutations in the p53 gene occur in diverse human tumour types

  1989cited by this paper
• Ras oncogene mutation in multiple myeloma

  1989cited by this paper
• High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene

  1989cited by this paper
• Plasma cell myeloma--new biological insights and advances in therapy.

  1989cited by this paper
• Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

  1989cited by this paper
• Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

  1989cited by this paper
• Analysis of RAS oncogene mutations in human lymphoid malignancies.

  1988cited by this paper
• A uniform deleting element mediates the loss of kappa genes in human B cells.

  1985cited by this paper
• A uniform deleting element mediates the loss of κ genes in human B cells

  1985cited by this paper
• Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells.

  1981cited by this paper
• A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

  1975cited by this paper
• Plasma cell leukemia. Report on 17 cases.

  1974cited by this paper
• Combination chemotherapy for multiple myeloma

  1972cited by this paper

• Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias

  2022cites this paper
• A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors

  2022cites this paper
• Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets

  2021cites this paper
• Multiple myeloma presenting as an intramedullary spinal cord tumor: a case report and review of the literature

  2020cites this paper
• Targeted Management Strategies in Multiple Myeloma

  2019cites this paper
• Unfavourable biological prognostic factors in Multiple Myeloma

  2019cites this paper
• Extramedullary disease in multiple myeloma - controversies and future directions.

  2019cites this paper
• MOLECULAR HETEROGENEITY OF MULTIPLE MYELOMA: THE BIOLOGICAL AND CLINICAL RELEVANCE OF NOVEL GENE MUTATIONS BY NEXT GENERATION SEQUENCING

  2018cites this paper
• The NF-κB Activating Pathways in Multiple Myeloma

  2018cites this paper
• Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion

  2017cites this paper
• De Novo Plasma-Cell Leukemia : About A Case

  2017cites this paper
• USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.

  2017cites this paper
• USP 7 inhibition alters homologous recombination repair and targets CLL cells independent of ATM / p 53 functional status Running title : USP 7 INHIBITION TARGETS ATM AND P 53 DEFECTIVE CLL

  2017cites this paper
• Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature

  2016cites this paper
• Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses

  2016cites this paper
• Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant

  2016cites this paper
• Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.

  2015cites this paper
• PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma

  2015cites this paper
• An update on molecular biology and drug resistance mechanisms of multiple myeloma.

  2015cites this paper
• Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns

  2015cites this paper
• An epidemiological study of multiple myeloma in Southern Africa

  2014cites this paper
• Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma.

  2014cites this paper
• A p53‐Dependent Tumor Suppressor Network Is Induced by Selective miR‐125a‐5p Inhibition in Multiple Myeloma Cells

  2014cites this paper
• Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe.

  2013cites this paper
• Biological and Clinical Implications of Exon 8 P53 (R282W) GeneMutation in Relation to Development and Progression of Chronic MyeloidLeukaemia Patients in India Population

  2013cites this paper
• Use of in vitro primary culture models to investigate the activity of standard and novel therapies in haematological malignancies

  2013cites this paper
• Genomic instability in multiple myeloma: mechanisms and therapeutic implications

  2013cites this paper
• Preclinical Development The Checkpoint Kinase Inhibitor AZD 7762 Potentiates Chemotherapy-Induced Apoptosis of p 53-Mutated Multiple Myeloma Cells

  2012cites this paper
• The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells

  2012cites this paper
• Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA

  2012cites this paper
• Preclinical Development Drug Resistance to Inhibitors of the Human Double Minute-2 E 3 Ligase Is Mediated by Point Mutations of p 53 , but Can Be Overcome with the p 53 Targeting Agent RITA

  2012cites this paper
• Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.

  2012cites this paper
• How I treat plasma cell leukemia.

  2012cites this paper
• Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX

  2011cites this paper
• The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.

  2011cites this paper
• The importance of protein profiling in the diagnosis and treatment of hematologic malignancies.

  2011cites this paper
• Multiple myeloma: current perspectives.

  2011cites this paper
• 广西地区非小细胞肺癌中K-ras基因点突变的研究

  2011cites this paper
• Primary plasma cell leukemia and autologous stem cell transplantation

  2010cites this paper
• Mieloma Múltiple: Alteraciones génicas y cromosómicas no translocacionales y sus implicaciones pronósticas

  2010cites this paper
• Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

  2010cites this paper
• Bortezomib-induced Apoptosis in the Treatment of Non-small Cell Lung Cancer

  2009cites this paper
• p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma.

  2009cites this paper
• The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to Mdm2 inhibitor-mediated apoptosis

  2008cites this paper
• An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.

  2008cites this paper
• Molecular and transcriptional characterization of 17p loss in B‐cell chronic lymphocytic leukemia

  2008cites this paper
• Alterações moleculares no Mieloma Múltiplo Molecular abnormalities in Multiple Myeloma

  2007cites this paper
• Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53

  2007cites this paper
• Molecular and transcriptional characterization of the novel 17p11.2‐p12 amplicon in multiple myeloma

  2007cites this paper
• Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.

  2007cites this paper
• Molecular pathogenesis of multiple myeloma.

  2007cites this paper
• Transcription Factors as Therapeutic Targets in Lymphoid Malignancies

  2007cites this paper
• Molecular biology of myeloma

  2007cites this paper
• Genetic events in the pathogenesis of multiple myeloma.

  2007cites this paper
• FISH panels for hematologic malignancies

  2007cites this paper
• Ploidy status rarely changes in myeloma patients at disease progression.

  2006cites this paper
• Selective Pharmacologic Activation of the p53-Dependent Pathway as a Therapeutic Strategy for Hematologic Malignancies

  2006cites this paper
• EXPRESSION IN HAEMATOLOGICAL MALIGNANCIES : RESPONSE TO ALKYLATING AGENT IN THE COMET ASSAY

  2006cites this paper
• Clinical implications of chromosomal abnormalities in multiple myeloma

  2006cites this paper
• Cytogenetics and molecular cytogenetics in multiple myeloma.

  2006cites this paper
• Role of osteoblast suppression in multiple myeloma

  2006cites this paper
• Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.

  2005cites this paper
• Prognostic impact of cytogenetic aberrations in patients with multiple myeloma or monoclonal gammopathy of unknown significance

  2005cites this paper
• Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis

  2005cites this paper
• Genetics and Cytogenetics of Multiple Myeloma

  2004cites this paper
• Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report

  2004cites this paper
• Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions

  2004cites this paper
• Solitary plasmacytoma of the skull: immunohistochemical study of angiogenic factors and syndecan-1--two case reports.

  2004cites this paper
• Flow cytometric analysis of DNA indices, expression of p53 and multidrug resistance genes in multiple myeloma patients.

  2004cites this paper
• p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.

  2004cites this paper
• Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma

  2004cites this paper
• Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma.

  2003cites this paper
• A possible role of the P53 gene deletion as a prognostic factor in multiple myeloma

  2003cites this paper
• Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.

  2003cites this paper
• Potential usefulness of serum p53 for laboratory management of plasma cell dyscrasias.

  2003cites this paper
• Tumour‐associated antigens in multiple myeloma

  2003cites this paper
• Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.

  2003cites this paper
• Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling

  2003cites this paper
• Multistep Tumorigenesis of Multiple Myeloma: Its Molecular Delineation

  2003cites this paper
• New insights into the pathophysiology of multiple myeloma.

  2003cites this paper
• Lack of Bcl10 gene mutations in laryngeal squamous cell carcinoma

  2002cites this paper
• New developments and treatment in multiple myeloma: new insights on molecular biology.

  2002cites this paper
• Functional significance of genetic abnormalities in multiple myeloma.

  2002cites this paper
• CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells.

  2002cites this paper
• CD40-mediated apoptosis in murine B-lymphoma lines containing mutated p53.

  2002cites this paper
• Chromosomal and genetic abnormalities in myeloma.

  2002cites this paper
• p63 in Laryngeal Squamous Cell Carcinoma: Evidence for a Role of TA-p63 Down-Regulation in Tumorigenesis and Lack of Prognostic Implications of p63 Immunoreactivity

  2002cites this paper
• Autocrine Production and Synergistic Growth-Promoting Activity of Interleukin-6 and Oncostatin M in a New Human Myeloma Cell Line TU-1

  2002cites this paper
• CD 40 activation induces p 53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells

  2002cites this paper
• Molecular aspects of multiple myeloma

  2002cites this paper
• Multiple myeloma: evolving genetic events and host interactions

  2002cites this paper
• The biology and cytogenetics of multiple myeloma.

  2002cites this paper
• Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines.

  2002cites this paper
• Molecular genetic methods in the diagnosis of hematologic neoplasms.

  2002cites this paper
• Chromosomal and genetic abnormalities in myeloma

  2002cites this paper
• Mutations of the p 53 and ras Genes in Childhood t ( l ; 19 )-Acute Lymphoblastic Leukemia

  2002cites this paper
• Increased risk for cancer in multiple myeloma patients and their first-degree relatives.

  2001cites this paper
• Significance of p53 mutations in patients with chronic lymphocytic leukemia

  2001cites this paper
• Abnormalities of the p53 Tumour Suppressor Gene in Mature B-cell Neoplasms

  2001cites this paper
• Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines.

  2001cites this paper